{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:18:05Z","timestamp":1790191085842,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T00:00:00Z","timestamp":1318377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Oral prochlorperazine (PCZ), an antiemetic, undergoes extensive first\u2010pass metabolism. The study developed a simultaneous analytical method for PCZ and its major metabolites, prochlorperazine sulfoxide (PCZSO), <jats:italic>N<\/jats:italic>\u2010demethylprochlorperazine (NDPCZ) and 7\u2010hydroxyprochlorperazine (PCZOH), in human plasma using an isocratic liquid chromatography\u2013tandem mass spectrometry (LC\u2010MS\/MS) method. Deproteinized plasma specimens were separated using a 3\u2009\u00b5m particle size octadecylsilyl column, and the run time was 10\u2009min. The calibration curves were linear over the concentration ranges of 0.01\u201340\u2009\u00b5g\/L for PCZ, NDPCZ and PCZOH, and 0.05\u201380\u2009\u00b5g\/L for PCZSO. The intra\u2010 and inter\u2010assay precisions and accuracies were within 7.0 and 99\u2013104% and within 9.0 and 99\u2013105%, respectively. The lower limits of quantification in human plasma were 10\u2009ng\/L for PCZ, NDPCZ and PCZOH, and 50\u2009ng\/L for PCZSO. The validated method was applied to the determination of plasma samples in 37 cancer patients receiving PCZ. Large interindividual variations were observed in plasma concentrations of PCZ, PCZSO, NDPCZ and PCZOH (relative standard deviation, 89.4, 88.7, 86.4 and 78.2%, respectively). In conclusion, this simultaneous LC\u2010MS\/MS method with acceptable analytical performance can be helpful for evaluating the pharmacokinetics of PCZ, including the determination of its metabolites in cancer patients and in clinical research. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bmc.1725","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T07:58:01Z","timestamp":1318406281000},"page":"754-760","source":"Crossref","is-referenced-by-count":11,"title":["Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry"],"prefix":"10.1002","volume":"26","author":[{"given":"Masaki","family":"Tashiro","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy Hamamatsu University School of Medicine  1\u201020\u20101 Handayama, Higashi\u2010ku Hamamatsu Shizuoka 431\u20103192 Japan"},{"name":"Department of Clinical Pharmaceutics and Pharmacy Practice, Faculty of Pharmaceutical Sciences University of Shizuoka  52\u20101 Yada, Suruga\u2010ku Shizuoka Shizuoka 422\u20108526 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy Hamamatsu University School of Medicine  1\u201020\u20101 Handayama, Higashi\u2010ku Hamamatsu Shizuoka 431\u20103192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics and Pharmacy Practice, Faculty of Pharmaceutical Sciences University of Shizuoka  52\u20101 Yada, Suruga\u2010ku Shizuoka Shizuoka 422\u20108526 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy Hamamatsu University School of Medicine  1\u201020\u20101 Handayama, Higashi\u2010ku Hamamatsu Shizuoka 431\u20103192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.184"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0b013e31816ed047"},{"key":"e_1_2_7_4_1","first-page":"307","article-title":"Extrapyramidal reactions to metoclopramide and prochlorperazine","volume":"71","author":"Bateman DN","year":"1989","journal-title":"The Quarterly Journal of Medicine"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.11.324"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2000.108652"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005281044"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(89)90291-3"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03973.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(97)00371-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.01.015"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(97)00414-3"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1992.tb01279.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.10.002"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.275"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01427.x"},{"key":"e_1_2_7_17_1","first-page":"346","article-title":"Evaluation of prochlorperazine buccal tablets (Bukatel) and metoclopramide oral tablets in the treatment of acute emesis","volume":"97","author":"Singh S","year":"1999","journal-title":"Journal of the Indian Medical Association"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03021.x"},{"key":"e_1_2_7_19_1","unstructured":"US Food and Drug Administration.2001.Guidance for Industry. Bioanalytical Method Validation. Available at:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf(accessed 12 August 2011)."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2003.11.011"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.07.038"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.1725","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.1725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:31:50Z","timestamp":1760034710000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.1725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/bmc.1725"],"URL":"https:\/\/doi.org\/10.1002\/bmc.1725","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,12]]}}}